Medical Aesthetics News Portland, OR July 24, 2026 By Cosmetiq Medicine A clinical review published this week put a number on something injectors have been watching for three years: the facial changes that follow rapid weight loss on GLP-1 medications are now driving measurable demand for aesthetic treatment
Table 4 provides a summary of these warnings and precautions that are noted in the prescribing information for these products
doi: 10.1093/jbmr/zjae069 3 SilverJJEinhornTA
Conclusion Laboratory research has linked BPC-157 exposure to several signaling systems, including VEGFR2AkteNOS, Srccaveolin-1eNOS, FAKpaxillin, ERK1/2, and FBXO22BACH1
211 A recent randomized controlled trial involving patients with heart failure with preserved ejection fraction and obesity demonstrated that 52 weeks of treatment with tirzepatide not only improved patient health status but also reduced the risk of a composite endpoint of cardiovascular death or worsening heart failure